Open Access. Powered by Scholars. Published by Universities.®

Physical Sciences and Mathematics Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 3 of 3

Full-Text Articles in Physical Sciences and Mathematics

Epidemiology Of Cancers In Men Who Have Sex With Men (Msm): A Protocol For Umbrella Review Of Systematic Reviews, Manoj Kumar Honaryar, Yelena Tarasenko, Maribel Almonte, Vitaly Smelov Jul 2020

Epidemiology Of Cancers In Men Who Have Sex With Men (Msm): A Protocol For Umbrella Review Of Systematic Reviews, Manoj Kumar Honaryar, Yelena Tarasenko, Maribel Almonte, Vitaly Smelov

Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

While earlier studies on men having sex with men (MSM) tended to examine infection-related cancers, an increasing number of studies have been focusing on effects of sexual orientation on other cancers and social and cultural causes for cancer disparities. As a type of tertiary research, this umbrella review (UR) aims to synthesize findings from existing review studies on the effects of sexual orientation on cancer. Relevant peer-reviewed systematic reviews (SRs) will be identified without date or language restrictions using MEDLINE, Cochrane Database of Systematic Reviews, and the International Prospective Register for Systematic Reviews, among others. The research team members will …


A Web-Based, Positive Emotion Skills Intervention For Enhancing Posttreatment Psychological Well-Being In Young Adult Cancer Survivors (Empower): Protocol For A Single-Arm Feasibility Trial, John M. Salsman, Laurie E. Mclouth, Michael Cohn, Janet A. Tooze, Mia Sorkin, Judith T. Moskowitz May 2020

A Web-Based, Positive Emotion Skills Intervention For Enhancing Posttreatment Psychological Well-Being In Young Adult Cancer Survivors (Empower): Protocol For A Single-Arm Feasibility Trial, John M. Salsman, Laurie E. Mclouth, Michael Cohn, Janet A. Tooze, Mia Sorkin, Judith T. Moskowitz

Behavioral Science Faculty Publications

BACKGROUND: Adolescent and young adult cancer survivors (AYAs) experience clinically significant distress and have limited access to supportive care services. Interventions to enhance psychological well-being have improved positive affect and reduced depression in clinical and healthy populations but have not been routinely tested in AYAs.

OBJECTIVE: The aim of this protocol is to (1) test the feasibility and acceptability of a Web-based positive emotion skills intervention for posttreatment AYAs called Enhancing Management of Psychological Outcomes With Emotion Regulation (EMPOWER) and (2) examine proof of concept for reducing psychological distress and enhancing psychological well-being.

METHODS: The intervention development and testing are …


Comparative Survival Of Asian And White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel, Susan Halabi, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson Jr., Kim N. Chi, Johann S. De Bono, John C. Araujo, Christopher Logothetis, Mario A. Eisenberger, David I. Quinn, Karim Fizazi, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small, William Kevin Kelly Jan 2020

Comparative Survival Of Asian And White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel, Susan Halabi, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson Jr., Kim N. Chi, Johann S. De Bono, John C. Araujo, Christopher Logothetis, Mario A. Eisenberger, David I. Quinn, Karim Fizazi, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small, William Kevin Kelly

Mathematics & Statistics Faculty Publications

There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] = 17.4 to 22.1 months) and 21.2 months (95% …